A Study of GR1803 in Systemic Lupus Erythematosus
Recruiting · NCT07348055 · Interventional (participants receive a specific treatment) · Lead sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
GR1803 injection
What this trial is about
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Who can take part
Age range
18 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- comfirmed diagnosis of systemic lupus erythematosus
- SLEDAI-2K≥6分
- written informed consent and ability to comply with protocol requirements
- have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months
Exclusion criteria
- with unstable acute and chronic diseases
- active infection
- history of malignant tumor within 5 years
Where it is running
1 location listed.
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan, Hubei, China